This trial is conducted in Europe. The aim of this trial is to compare the exposure of liraglutide in young versus elderly healthy subjects.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
32
A single dose of 1 mg administered subcutaneously (under the skin)
Novo Nordisk Investigational Site
Berlin, Germany
Area under the liraglutide plasma concentration time curve (AUC 0-t)
Area under the liraglutide plasma concentration time curve (AUC 0-infinity)
Cmax, maximum liraglutide plasma concentration
tmax, time to reach Cmax
t½, terminal plasma elimination half-life
Adverse events
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.